Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;44(6):2203-2216.
doi: 10.1007/s10753-021-01493-0. Epub 2021 Jun 6.

Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue

Affiliations

Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue

Caglar Berkel et al. Inflammation. 2021 Dec.

Abstract

Gasdermins (GSDM) are members of a family of pore-forming effector proteins which lead to membrane permeabilization and pyroptosis, a lytic cell death with pro-inflammatory characteristics. Recently, two members of the gasdermin family, gasdermin B (GSDMB) and gasdermin E (GSDME), were shown to suppress tumor growth, through the involvement of cytotoxic lymphocytes. Other studies also reported the important functions of gasdermins in various cancer types including gastric cancer, hepatocarcinoma, and cervix and breast cancer. However, gasdermins have not been previously studied in the context of serous ovarian cancer. Here, we showed that gasdermin D (GSDMD) and gasdermin C (GSDMC) expression increases in serous ovarian cancer; in contrast, the expression of GSDME and PJVK (Pejvakin, DFNB59) is downregulated, compared to healthy ovaries, in multiple independent gene expression datasets. We found that copy number gains are highly frequent (present in approximately 50% of patients) in genes encoding GSDMD and GSDMC in ovarian cancer, in line with their upregulated expression in serous ovarian cancer. Moreover, we observed that the expression of GSDMB and GSDMD, but not of GSDME, is different among several histotypes of epithelial ovarian cancer. Therefore, we propose that differential expression and copy number variations of certain gasdermins might be associated with the development of serous ovarian cancer, in which different members of the family have distinct functions; however, further research is required in in vivo models to understand how changes in gasdermin family members mechanistically contribute to serous ovarian cancer.

Keywords: epithelial ovarian cancer; gasdermin; gasdermin D (GSDMD); gasdermin E (GSDME); inflammation; pyroptosis; serous ovarian cancer, tumor initiation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ferlay, J., I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, and F. Bray. 2015 Mar 1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136 (5): E359–E386. https://doi.org/10.1002/ijc.29210 . - DOI - PubMed
    1. Berkel, C., and E. Cacan. 2021. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer. Hum Cell. 34: 862–877. https://doi.org/10.1007/s13577-021-00486-3 . - DOI - PubMed
    1. Bristow, R.E., R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz. 2002 Mar 1. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 20 (5): 1248–1259. https://doi.org/10.1200/JCO.2002.20.5.1248 . - DOI - PubMed
    1. Kyrgiou, M., G. Salanti, N. Pavlidis, E. Paraskevaidis, and J.P. Ioannidis. 2006. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 98 (22): 1655–1663. https://doi.org/10.1093/jnci/djj443 . - DOI - PubMed
    1. Coukos, G., J. Tanyi, and L.E. Kandalaft. 2016. Opportunities in immunotherapy of ovarian cancer. Ann Oncol (Suppl 1): i11–i15. https://doi.org/10.1093/annonc/mdw084 PMID: 27141063; PMCID: PMC4852275.

MeSH terms

LinkOut - more resources